Rocket Lab Q2 Beat Highlights Strength, But Neutron and Iridium Gaps Keep Valuation Extended

What happened

Rocket Lab's Q2 earnings call emphasized record Q3 revenue guidance, Neutron scaling, and the planned Iridium acquisition as central to its space platform strategy. The quarter delivered 62% revenue growth to $234.1 million and a record $2.36 billion backlog, driven largely by defense and space systems. However, Neutron's timeline remains tight with pad delivery targeted for Q4 2026 but no completed qualification, while Iridium still lacks an S-4 filing and permanent financing beyond a $3.6 billion bridge. Notably, the CEO's concentrated share sales in July add caution, suggesting insiders may see limited near-term upside at current prices. Overall, the earnings call reaffirms operational momentum but does not de-risk the two biggest valuation bridges.

Implication

The Q2 earnings call reinforces Rocket Lab's execution strength and defense demand, yet the stock's valuation already embeds Neutron commercialization and Iridium close. Without concrete de-risking — Neutron qualification, Iridium S-4, and permanent financing — the current price offers limited margin of safety. Investors should await either a pullback toward the $65 entry or clear evidence that these platform-scale catalysts are on track.

Thesis delta

The earnings call adds no new de-risking information; it confirms strong operations but does not advance the two biggest valuation bridges (Neutron and Iridium). The WAIT call remains appropriate, with the bull case still dependent on milestones that are not yet achieved.